This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Radient Technologies Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Radient Technologies's earnings have been declining at an average annual rate of -2.8%, while the Pharmaceuticals industry saw earnings growing at 19.4% annually. Revenues have been growing at an average rate of 15.3% per year.
Belangrijke informatie
-2.8%
Groei van de winst
9.9%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 7.3% |
| Inkomstengroei | 15.3% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -359.0% |
| Laatste winstupdate | 31 Dec 2022 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Radient Technologies geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 22 | 3 | -11 | 3 | 0 |
| 30 Sep 22 | 4 | -13 | 4 | 0 |
| 30 Jun 22 | 3 | -12 | 3 | 0 |
| 31 Mar 22 | 4 | -13 | 4 | 0 |
| 31 Dec 21 | 4 | -29 | 5 | 0 |
| 30 Sep 21 | 4 | -37 | 6 | 1 |
| 30 Jun 21 | 3 | -39 | 7 | 1 |
| 31 Mar 21 | 2 | -42 | 9 | 1 |
| 31 Dec 20 | 8 | -39 | 12 | 1 |
| 30 Sep 20 | 17 | -33 | 14 | 2 |
| 30 Jun 20 | 18 | -36 | 16 | 3 |
| 31 Mar 20 | 18 | -37 | 17 | 3 |
| 31 Dec 19 | 13 | -26 | 16 | 5 |
| 30 Sep 19 | 1 | -34 | 24 | 4 |
| 30 Jun 19 | 0 | -31 | 23 | 3 |
| 31 Mar 19 | 0 | -28 | 21 | 2 |
| 31 Dec 18 | 0 | -23 | 18 | 1 |
| 30 Sep 18 | 0 | -14 | 10 | 1 |
| 30 Jun 18 | 0 | -12 | 9 | 1 |
| 31 Mar 18 | 0 | -14 | 11 | 0 |
| 31 Dec 17 | 0 | -12 | 11 | 0 |
| 30 Sep 17 | 0 | -10 | 8 | 0 |
| 30 Jun 17 | 0 | -9 | 7 | 0 |
| 31 Mar 17 | 0 | -4 | 3 | 0 |
| 31 Dec 16 | 0 | -4 | 2 | 0 |
| 30 Sep 16 | 1 | -3 | 2 | 0 |
| 30 Jun 16 | 1 | -4 | 3 | 0 |
| 31 Mar 16 | 1 | -4 | 3 | 0 |
| 31 Dec 15 | 1 | -11 | 3 | 0 |
| 30 Sep 15 | 0 | -11 | 3 | 0 |
| 30 Jun 15 | 0 | -12 | 4 | 1 |
| 31 Mar 15 | 0 | -14 | 4 | 1 |
| 31 Dec 14 | 0 | -8 | 4 | 1 |
| 30 Sep 14 | 0 | -9 | 4 | 1 |
| 30 Jun 14 | 0 | -8 | 3 | 1 |
| 31 Mar 14 | 0 | -5 | 3 | 1 |
| 31 Dec 13 | 0 | -5 | 3 | 1 |
| 31 Mar 13 | 0 | -3 | 3 | 0 |
Kwaliteitswinsten: RD8 is currently unprofitable.
Groeiende winstmarge: RD8 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: RD8 is unprofitable, and losses have increased over the past 5 years at a rate of 2.8% per year.
Versnelling van de groei: Unable to compare RD8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: RD8 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.1%).
Rendement op eigen vermogen
Hoge ROE: RD8's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.